RT Journal Article
SR Electronic
T1 Monoclonal Antibodies: What the Diagnostic Neuroradiologist Needs to Know
JF American Journal of Neuroradiology
JO Am. J. Neuroradiol.
FD American Society of Neuroradiology
SP 1358
OP 1366
DO 10.3174/ajnr.A7974
VO 44
IS 12
A1 R. Alsufayan
A1 C. Hess
A1 T. Krings
YR 2023
UL http://www.ajnr.org/content/44/12/1358.abstract
AB Monoclonal antibodies have become increasingly popular as novel therapeutics against a variety of diseases due to their specificity, affinity, and serum stability. Due to the nearly infinite repertoire of monoclonal antibodies, their therapeutic use is rapidly expanding, revolutionizing disease course and management, and what is now considered experimental therapy may soon become approved practice. Therefore, it is important for radiologists, neuroradiologists, and neurologists to be aware of these drugs and their possible different imaging-related manifestations, including expected and adverse effects of these novel drugs. Herein, we review the most commonly used monoclonal antibody–targeted therapeutic agents, their mechanism of action, clinical applications, and major adverse events with a focus on neurologic and neurographic effects and discuss differential considerations, to assist in the diagnosis of these conditions.AbantibodyAEadverse eventAgantigenARIAamyloid-related imaging abnormalitiesCAAcerebral amyloid angiopathyCTLA-4cytotoxic T-lymphocyte Ag 4Fcconstant fragmentIRAEimmune-related AEIRISimmune reconstitution inflammatory syndromemAbmonoclonal antibodyNTZnatalizumabPMLprogressive multifocal leukoencephalopathyPRESposterior reversible encephalopathy syndromeTNFtumor necrosis factor